Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.

U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...

On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

The agency also is reviewing safety of immunizations for RSV, according to manufacturers of the therapies who have been ...

Food and Drug Administration officials have opened a safety review of two injectable drugs used to protect babies and ...

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk. By Gina Kolata Merck, the company that introduced statins to the ...

Merck (NYSE:MRK) announced on Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Enflonsia, a prophylactic antibody therapy developed by the company to ...

Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season If approved by the European ...